Literature DB >> 9543144

The modulation of the human sodium iodide symporter activity by Graves' disease sera.

R A Ajjan1, C Findlay, R A Metcalfe, P F Watson, M Crisp, M Ludgate, A P Weetman.   

Abstract

The transport of iodide into the thyroid, catalyzed by the Na+/I- symporter (NIS), is the initial and rate-limiting step in the formation of thyroid hormones. To study the basic characteristics of the human (h) NIS, we have established a Chinese hamster ovary cell line stably expressing the hNIS (CHO-NIS9). In agreement with previous work on the rat NIS, iodide uptake in these cells was initiated within 2 min of the addition of 131I, reaching a plateau after 30 min. Both perchlorate and thiocyanate inhibited iodide uptake in a dose-dependent manner, with inhibition evident at concentrations of 0.01 and 0.1 micromol/L, respectively, and reaching complete inhibition at 20 micromol/L and 500 micromol/L, respectively. Ouabain, which blocks the activity of the Na+/K+ adenosine triphosphatase, also inhibited iodide uptake in a dose-dependent manner, starting at concentrations of 100 micromol/L and reaching maximum inhibition at 1600 micromol/L, indicating that iodide uptake in these cells is sodium dependent. CHO-NIS9 cells were further used to study 88 sera from patients with Graves' disease, for iodide uptake inhibitory activity, which were compared with sera from 31 controls. Significant iodide uptake inhibition was taken as any inhibition in excess of the mean + 3 SD of the results with the control sera. On this basis, 27 (30.7%) of the Graves' sera, but none of the controls, inhibited iodide uptake in CHO-NIS9. IgGs from these patients also inhibited iodide uptake, indicating that this inhibitory activity was antibody mediated. In summary, we have established a CHO cell line stably expressing the hNIS and shown that antibodies in GD sera can inhibit iodide uptake in these cells. This further emphasizes the role of NIS as a novel autoantigen in thyroid immunity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9543144     DOI: 10.1210/jcem.83.4.4701

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Autoimmune thyroid disease and breast cancer: a chance association?

Authors:  P P Smyth
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

2.  Identification of antigenic domains on the human sodium-iodide symporter which are recognized by autoantibodies from patients with autoimmune thyroid disease.

Authors:  E H Kemp; E A Waterman; R A Ajjan; K A Smith; P F Watson; M E Ludgate; A P Weetman
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  Expression of sodium iodide symporter in benign and malignant human thyroid tissues.

Authors:  J D Lin; C Hsueh; T C Chao; H F Weng
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

4.  The sodium iodide symporter is unlikely to be a thyroid/breast shared antigen.

Authors:  I Muller; L Zhang; C Giani; C M Dayan; M E Ludgate; F Grennan-Jones
Journal:  J Endocrinol Invest       Date:  2015-08-08       Impact factor: 4.256

5.  Autoimmune thyroid disorders-An update.

Authors:  Manorama Swain; Truptirekha Swain; Binoy Kumar Mohanty
Journal:  Indian J Clin Biochem       Date:  2005-01

Review 6.  Molecular Insights Into the Relationship Between Autoimmune Thyroid Diseases and Breast Cancer: A Critical Perspective on Autoimmunity and ER Stress.

Authors:  Safikur Rahman; Ayyagari Archana; Arif Tasleem Jan; Durgashree Dutta; Abhishek Shankar; Jihoe Kim; Rinki Minakshi
Journal:  Front Immunol       Date:  2019-03-01       Impact factor: 7.561

Review 7.  The thyroid, iodine and breast cancer.

Authors:  Peter P A Smyth
Journal:  Breast Cancer Res       Date:  2003-07-29       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.